Pharmacologic Support of the Failing Heart

Surgical Clinics of North America

Volumn 86, Issue 6, 2006, Pages 1503-1521

  London, Jason A ^a   Sena, Matthew J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ANTIBIOTIC AGENT; CARDIOTONIC AGENT; CATECHOLAMINE; CILOSTAZOL; CLOPIDOGREL; CORTICOSTEROID; DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; HEPARIN; INOTROPIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; MILRINONE; NITRATE; NITROPRUSSIDE SODIUM; NORADRENALIN; OXYGEN; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITOR; TETRACOSACTIDE; THROMBIN INHIBITOR; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; VASOPRESSIN;

ACUTE HEART INFARCTION; ANAPHYLACTIC SHOCK; ANTIBIOTIC THERAPY; ANTICOAGULATION; AORTA BALLOON; BLEEDING; BLOOD OXYGENATION; BLOOD VESSEL; CARDIOGENIC SHOCK; CARDIOVASCULAR EFFECT; CLINICAL ASSESSMENT; COMORBIDITY; CORTICOSTEROID THERAPY; CRITICALLY ILL PATIENT; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; EARLY INTERVENTION; HEART CONDUCTION; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART INNERVATION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE REVASCULARIZATION; HEART PERFUSION; HEART RIGHT VENTRICLE FAILURE; HEART SEPTUM DEFECT; HEMODYNAMIC MONITORING; HEMORRHAGIC SHOCK; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INFECTION; LOW DRUG DOSE; MORTALITY; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PULMONARY ARTERY CATHETER; RECURRENT DISEASE; REVIEW; SEPTIC SHOCK; THROMBOSIS; UNSTABLE ANGINA PECTORIS; VALVULAR HEART DISEASE;

ALGORITHMS; BLOOD VESSELS; CATHETERIZATION, SWAN-GANZ; GLUCOCORTICOIDS; HEART; HEART CONDUCTION SYSTEM; HEART DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; OXYGEN CONSUMPTION; SHOCK, CARDIOGENIC; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS; VASOPRESSINS;

EID: 33751012976     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2006.08.003     Document Type: Review

References (82)

1. Rivers E., Ander D., and Powell D. Central venous oxygen saturation monitoring in the critically ill patient. Curr Opin Crit Care 7 (2001) 204-211
2. Zipes D.P., Bonow L.P., and Braunwald R. Braunwald's heart disease: a textbook of cardiovascular medicine, vol. 2. 7th edition (2005), Elsevier Saunders, Philadelphia
3. Guyton A.C., and Hall J.E. Textbook of medical physiology. 11th edition (2006), Elsevier Saunders, Philadelphia
4. Swan H.J., Ganz W., Forrester J., et al. Catheterization of the heart in man with use of a flow-directed balloon-tipped catheter. N Engl J Med 283 (1970) 447-451
5. Gore J.M., Goldberg R.J., Spodick D.H., et al. A community-wide assessment of the use of pulmonary artery catheters in patients with acute myocardial infarction. Chest 92 (1987) 721-727
6. Rhodes A., Cusack R.J., Newman P.J., et al. A randomised, controlled trial of the pulmonary artery catheter in critically ill patients. Intensive Care Med 28 (2002) 6-64
7. Binanay C., Califf R.M., Hasselblad V., et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 294 (2005) 1625-1633
8. Richard C., Warszawski J., Anguel N., et al. Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. JAMA 290 (2003) 2713-2720
9. Sandham J.D., Hull R.D., Brant R.F., et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 348 (2003) 5-14
10. Ullian M.E. The role of corticosteriods in the regulation of vascular tone. Cardiovasc Res 41 (1999) 55-64
11. Annane D., Sebille V., Troche G., et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 283 (2000) 1038-1045
12. Sam S., Corbridge T.C., Mokhlesi B., et al. Cortisol levels and mortality in severe sepsis. Clin Endocrinol (Oxf) 60 (2004) 29-35
13. Schroeder S., Wichers M., Klingmuller D., et al. The hypothalamic-pituitary-adrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone. Crit Care Med 29 (2001) 310-316
14. Marik P.E., and Zaloga G.P. Adrenal insufficiency during septic shock. Crit Care Med 31 (2003) 141-145
15. Annane D., Sebille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288 (2002) 862-871
16. Yildiz O., Doganay M., Aygen B., et al. Physiological-dose steroid therapy in sepsis. [ISRCTN36253388]. Crit Care 6 (2002) 251-259
17. Keh D., Boehnke T., Weber-Cartens S., et al. Immunologic and hemodynamic effects of low-dose hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 167 (2003) 512-520
18. Briegel J., Forst H., Haller M., et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 27 (1999) 723-732
19. Bollaert P.E., Charpentier C., Levy B., et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 26 (1998) 645-650
20. Dunser M.W., Wenzel V., Mayr A.J., et al. Management of vasodilatory shock: defining the role of arginine vasopressin. Drugs 63 (2003) 237-256
21. Holmes C.L., Patel B.M., Russell J.A., et al. Physiology of vasopressin relevant to management of septic shock. Chest 120 (2001) 989-1002
22. van Haren F.M., Rozendaal F.W., and van der Hoeven J.G. The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest 124 (2003) 2256-2260
23. Dunser M.W., Mayr A.J., Tur A., et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 31 (2003) 1394-1398
24. Landry D.W., Levin H.R., Gallant E.M., et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95 (1997) 1122-1125
25. Patel B.M., Chittock D.R., Russell J.A., et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96 (2002) 576-582
26. Walsh T.S., McClelland D.B., Lee R.J., et al. Prevalence of ischaemic heart disease at admission to intensive care and its influence on red cell transfusion thresholds: multicentre Scottish Study. Br J Anaesth 94 (2005) 445-452
27. Lim W., Qushmaq I., Cook D.J., et al. Elevated troponin and myocardial infarction in the intensive care unit: a prospective study. Crit Care 9 (2005) R636-R644
28. Stone P.H., Thompson B., Anderson H.V., et al. Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: the TIMI III registry. JAMA 275 (1996) 1104-1112
29. Hochman J.S., Boland J., Sleeper L.A., et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality: results of an International Registry. SHOCK Registry Investigators. Circulation 91 (1995) 873-881
30. Alpert J.S., Thygesen K., Antman E., et al. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 (2000) 959-969
31. Balk E.M., Ioannidis J.P., Salem D., et al. Accuracy of biomarkers to diagnose acute cardiac ischemia in the emergency department: a meta-analysis. Ann Emerg Med 37 (2001) 478-494
32. Vitarelli A., Tiukinhoy S., Di Luzio S., et al. The role of echocardiography in the diagnosis and management of heart failure. Heart Fail Rev 8 (2003) 181-189
33. Naughton M.T., Rahman M.A., Hara K., et al. Effect of continuous positive airway pressure on intrathoracic and left ventricular transmural pressures in patients with congestive heart failure. Circulation 91 (1995) 1725-1731
34. Marik P.E., and Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 272 (1994) 1354-1357
35. Levy B., Bollaert P.E., Charpentier C., et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med 23 (1997) 282-287
36. Meier-Hellmann A., Reinhart K., Bredle D.L., et al. Epinephrine impairs splanchnic perfusion in septic shock. Crit Care Med 25 (1997) 399-404
37. Zehender M., Kasper W., Kauder E., et al. Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction. N Engl J Med 328 (1993) 981-988
38. Lewis Jr. H.D., Davis J.W., Archibald D.G., et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 309 (1983) 396-403
39. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
40. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease: the RISC Group. Lancet 336 (1990) 827-830
41. Chu M.W., Wilson S.R., Novick R.J., et al. Does clopidogrel increase blood loss following coronary artery bypass surgery?. Ann Thorac Surg 78 (2004) 1536-1541
42. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
43. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 36 (2000) 970-1062
44. Le Nguyen M.T., and Spencer F.A. Low molecular weight heparin and unfractionated heparin in the early pharmacologic management of acute coronary syndromes: a meta-analysis of randomized clinical trials. J Thromb Thrombolysis 12 (2001) 289-295
45. Husted S., Becker R., and Kher A. A critical review of clinical trials for low-molecular-weight heparin therapy in unstable coronary artery disease. Clin Cardiol 24 (2001) 492-499
46. Ferguson J.J., Califf R.M., Antman E.M., et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292 (2004) 45-54
47. Petersen J.L., Mahaffey K.W., Hasselblad V., et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA 292 (2004) 89-96
48. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 44 (2004) 671-719
49. Bateman R.M., Sharpe M.D., and Ellis C.G. Bench-to-bedside review: microvascular dysfunction in sepsis-hemodynamics, oxygen transport, and nitric oxide. Crit Care 7 (2003) 359-373
50. Vincent J.L., and De Backer D. Microvascular dysfunction as a cause of organ dysfunction in severe sepsis. Crit Care 9 Suppl 4 (2005) S9-S12
51. De Backer D., Creteur J., Preiser J.C., et al. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 166 (2002) 98-104
52. Cohen E.S., and Hollenberg S.M. Tissue oxygenation and sepsis. Crit Care Med 29 (2001) 1479-1480
53. Beale R.J., Hollenberg S.M., Vincent J.L., et al. Vasopressor and inotropic support in septic shock: an evidence-based review. Crit Care Med 32 11 Suppl (2004) S455-S465
54. Shoemaker W.C., Appel P.L., Kram H.B., et al. Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest 94 (1988) 1176-1186
55. Tuchschmidt J., Fried J., Astiz M., et al. Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest 102 (1992) 216-220
56. Hayes M.A., Timmins A.C., Yau E.H., et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 330 (1994) 1717-1722
57. Gattinoni L., Brazzi L., Pelosi P., et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med 333 (1995) 1025-1032
58. Holcroft J. Shock. In: Fink J.G., Kaiser M.P., Pearce L.R., et al. (Eds). ACS surgery: principles and practice, vol. 1 (2005), WebMD, New York 1624
59. Martin C., Papazian L., Perrin G., et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?. Chest 103 (1993) 1826-1831
60. Sakr Y., Reinhart K., Vincent J.L., et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med 34 (2006) 589-597
61. Martin C., Viviand X., Leone M., et al. Effect of norepinephrine on the outcome of septic shock. Crit Care Med 28 (2000) 2758-2765
62. Kumar A., Thota V., Dee L., et al. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 183 (1996) 949-958
63. Cain B.S., Meldrum D.R., Dinarello C.A., et al. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med 27 (1999) 1309-1318
64. Kumar A., Brar R., Wang P., et al. Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol 276 1 Pt 2 (1999) R265-R276
65. Dhainaut J.F., Brunet F., Monsallier J.F., et al. Bedside evaluation of right ventricular performance using a rapid computerized thermodilution method. Crit Care Med 15 (1987) 148-152
66. Poelaert J., Declerck C., Vogelaers D., et al. Left ventricular systolic and diastolic function in septic shock. Intensive Care Med 23 (1997) 553-560
67. Parker M.M., Shelhamer J.H., Bacharach S.L., et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 100 (1984) 483-490
68. Monsalve F., Rucabado L., Salvador A., et al. Myocardial depression in septic shock caused by meningococcal infection. Crit Care Med 12 (1984) 1021-1023
69. Munt B., Jue J., Gin K., et al. Diastolic filling in human severe sepsis: an echocardiographic study. Crit Care Med 26 (1998) 1829-1833
70. Dhainaut J.F., Lanore J.J., de Gournay J.M., et al. Right ventricular dysfunction in patients with septic shock. Intensive Care Med 14 Suppl 2 (1988) 488-491
71. Vincent J.L., Thirion M., Brimioulle S., et al. Thermodilution measurement of right ventricular ejection fraction with a modified pulmonary artery catheter. Intensive Care Med 12 (1986) 33-38
72. De Backer D., Creteur J., Silva E., et al. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best?. Crit Care Med 31 (2003) 1659-1667
73. Landry D.W., and Oliver J.A. The pathogenesis of vasodilatory shock. N Engl J Med 345 (2001) 588-595
74. Landry D.W., Levin H.R., Gallant E.M., et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 25 (1997) 1279-1282
75. Malay M.B., Ashton Jr. R.C., Landry D.W., et al. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 47 (1999) 699-703 [discussion: 703-5]
76. Dunser M.W., Mayr A.J., Ulmer H., et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 107 (2003) 2313-2319
77. Sharma R.M., and Setlur R. Vasopressin in hemorrhagic shock. Anesth Analg 101 (2005) 833-834
78. Krismer A.C., Wenzel V., Voelckel W.G., et al. Employing vasopressin as an adjunct vasopressor in uncontrolled traumatic hemorrhagic shock: three cases and a brief analysis of the literature. Anesthetist 54 (2005) 220-224
79. Kill C., Wranze E., and Wulf H. Successful treatment of severe anaphylactic shock with vasopressin: two case reports. Int Arch Allergy Immunol 134 (2004) 260-261
80. Jolly S., Newton G., Horlick E., et al. Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 96 (2005) 1617-1620
81. Tsuneyoshi I., Onomoto M., Yonetani A., et al. Low-dose vasopressin infusion in patients with severe vasodilatory hypotension after prolonged hemorrhage during general anesthesia. J Anesth 19 (2005) 170-173
82. Minneci P.C., Deans K.J., Banks S.M., et al. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 141 (2004) 47-56